DR. LAL PATH LABS LTD. (539524) — Latest Corporate Announcements
₹1,917.6
₹-52.10 (-2.65%)
Market Cap
₹32,064.33 Cr
P/E Ratio
59.19
52W Range
₹1272.6 – ₹2038.6
Board Meeting Intimations
📅 Scheduled Board Meeting & Agenda
Meeting Date: 04-Nov-2026
Agenda / Purpose: Financial Results/Other business matters
Timeline: In 22 days
Corporate Actions & Regulatory Filings
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Acquisition
Dr. Lal PathLabs Ltd - 539524 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Dr. Lal PathLabs Ltd - 539524 - Intimation Under Regulation 30
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Dr. Lal PathLabs Ltd - 539524 - Closure of Trading Window
Dr. Lal PathLabs Ltd - 539524 - Board Meeting Intimation for The Quarter And Half Year Ending On September 30, 2026
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Acquisition
Dr. Lal PathLabs Ltd - 539524 - Board Meeting Outcome for Outcome Of Board Meeting Dated September 24, 2026
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Newspaper Publication
To consider and approve the financial results for the period ending Jun 30, 2026 and other business mattersPlease note that this Board Meeting pertains to the Financial Year 2026 2027. However, while submitting this announcement, the Financial Year is being auto-populated as 2025 2026. Since this field is system-generated and cannot be modified by us, we are submitting the announcement with the Financial Year reflecting as 2025 2026.We request you to kindly take note of the above and consider this announcement as pertaining to the Financial Year 2026 2027.
To consider and approve the financial results for the period ended March 31, 2026 and other business matters
To consider and approve the financial results for the period ended December 31, 2025 and other business matters
To consider and approve the financial results for the period ended September 30, 2025, dividend and to consider issuing bonus shares and other business matters
To consider and approve the financial results for the period ended Jun 30, 2025, dividend and other business matters
To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters
To consider and approve the financial results for the period ended December 31, 2024, dividend, if any and other business matters
To consider and approve the un-audited financial results (Standalone and Consolidated) for the period ended September 30, 2024, dividend, if any and other business matters
To consider and approve the financial results for the period ended Jun 30, 2024, dividend and other business matters
To consider and approve the financial results for the period ended March 31, 2024, recommendation of final dividend, if any and other business matters
Financial Results (Quarterly & Annual)
| Quarter / Period | Meeting / Outcome Date | Status | Filing Details |
|---|---|---|---|
| Quarter Ended 30-Sep-2026 (Q2 FY27) | 04-Nov-2026 | Scheduled Upcoming | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| Quarter Ended 30-Jun-2026 (Q1 FY27) | 24-Jul-2026 | Declared | To consider and approve the financial results for the period ending Jun 30, 2026 and other business mattersPlease note that this Board Meeting pertains to the Financial Year 2026 2027. However, while submitting this announcement, the Financial Year is being auto-populated as 2025 2026. Since this field is system-generated and cannot be modified by us, we are submitting the announcement with the Financial Year reflecting as 2025 2026.We request you to kindly take note of the above and consider this announcement as pertaining to the Financial Year 2026 2027. |
| Year Ended 31-Mar-2026 (Q4 FY26) | 30-Apr-2026 | Declared | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| Quarter Ended 31-Dec-2025 (Q3 FY26) | 30-Jan-2026 | Declared | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| Quarter Ended 30-Sep-2025 (Q2 FY26) | 31-Oct-2025 | Declared | To consider and approve the financial results for the period ended September 30, 2025, dividend and to consider issuing bonus shares and other business matters |
| Quarter Ended 30-Jun-2025 (Q1 FY26) | 31-Jul-2025 | Declared | To consider and approve the financial results for the period ended Jun 30, 2025, dividend and other business matters |
| Year Ended 31-Mar-2025 (Q4 FY25) | 25-Apr-2025 | Declared | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
| Quarter Ended 31-Dec-2024 (Q3 FY25) | 30-Jan-2025 | Declared | To consider and approve the financial results for the period ended December 31, 2024, dividend, if any and other business matters |
| Quarter Ended 30-Sep-2024 (Q2 FY25) (STD & CONSOL) | 23-Oct-2024 | Declared | To consider and approve the un-audited financial results (Standalone and Consolidated) for the period ended September 30, 2024, dividend, if any and other business matters |
| Quarter Ended 30-Jun-2024 (Q1 FY25) | 07-Aug-2024 | Declared | To consider and approve the financial results for the period ended Jun 30, 2024, dividend and other business matters |
| Year Ended 31-Mar-2024 (Q4 FY24) | 10-May-2024 | Declared | To consider and approve the financial results for the period ended March 31, 2024, recommendation of final dividend, if any and other business matters |
| Quarter Ended 31-Dec-2023 (Q3 FY24) | 01-Feb-2024 | Declared | To consider and approve the financial results for the period ended December 31, 2023, dividend and other business matters |
Track Related Peer Equities
Related Research Guides & Regulatory Playbooks
Frequently Asked Questions about DR. LAL PATH LABS LTD. BSE Disclosures
What is the latest BSE announcement by DR. LAL PATH LABS LTD.?
The latest BSE disclosure by DR. LAL PATH LABS LTD. (LALPATHLAB), filed on 04-Nov-2026 , is: "To consider and approve the financial results for the period ended September 30, 2026 and other business matters". Bsenexus tracks every official filing for DR. LAL PATH LABS LTD. with AI-powered summaries on its announcements feed.
When is DR. LAL PATH LABS LTD.'s next board meeting?
DR. LAL PATH LABS LTD. has a board meeting scheduled for 04-Nov-2026 (in 22 days) to consider: Financial Results/Other business matters.
When does DR. LAL PATH LABS LTD. declare quarterly results?
Under SEBI (LODR) Regulation 33, listed companies submit quarterly unaudited results within 45 days of the quarter ending, and annual audited figures within 60 days. DR. LAL PATH LABS LTD.'s recent results history is tabulated above. Track scheduled board meetings on the Bsenexus Results Calendar.